Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Amazon Great Indian Festival 2020 - Electronics
Stock Report

| More

Panacea Biotec announces successful completion of Phase I / II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll

Posted On: 2020-09-24 00:25:57

Panacea Biotec has announced successful completion of its Phase I / II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose live-attenuated tetravalent vaccine.

According to the World Health Organization, Dengue represents one of the ten biggest global health threats, and it is critical that we have access to a safe and effective vaccine candidate that can reduce the devastating impact of Dengue fever in endemic regions.

Speaking on the occasion, Dr. Rajesh Jain, Managing Director, said "DengiAll's Phase I / II study results are even more important in the context of the Covid-19 pandemic. Co-infection of Dengue and Covid-19 in a Dengue endemic India may complicate approach to treatment and strain health care infrastructure. Panacea Biotec has already approached the DGCI to seek accelerated review of its data to bring DengiAll to market quickly and reduce burden on our healthcare infrastructure."

Dr. Lalitendu Mohanty, Head of Clinical Research, said, "Dengue fever's unique characteristics make vaccine development tricky and an ideal Dengue vaccine must be safe and offer balanced and robust immune response against all four Dengue serotypes. This is where, we believe that DengiAll has shown promising results. I would like to thank virologist Dr. Steven Whitehead and the team at the National Institute of Allergy and Infectious Disease, US and infectious disease specialist Dr. Anna Durbin at the John Hopkins School of Public Health for their continued and unfettered support in this journey to bring DengiAll to market."

Mr. Devender Gupta, Chief Financial Officer, said, "We would like to thank Technology Development Board, Ministry of Science and Technology for supporting Panacea Biotec through financial and technical resources to make DengiAll's Phase I / II Clinical Trials a success."

DengiAll has illustrated the strength of Panacea Biotec's expertise in vaccinology, research, development, and manufacturing while leveraging NIH's ability to work on complex biological challenges to develop breakthrough technologies. Panacea Biotec through continued support from National Institutes of Health, Technology Development Board, and other stakeholders is in a better position to increase affordable access to DengiAll to fight Dengue, a disease that has eluded mankind for generations. With more than 3.9 billion people living in Dengue endemic areas and over 390 million infections per year, DengiAll targets a global market of over $3 billion.

Shares of PANACEA BIOTEC LTD. was last trading in BSE at Rs.187 as compared to the previous close of Rs. 185.55. The total number of shares traded during the day was 11816 in over 320 trades.

The stock hit an intraday high of Rs. 194.35 and intraday low of 184. The net turnover during the day was Rs. 2212655.

Source: Equity Bulls

Click here to send ur comments or to

Amazon Great Indian Festival 2020 - Mobiles

Other Headlines:

Rossari Biotech announces Q2 & H1 FY21 results

Tata Metaliks Ltd restarts operations of furnace from today

Rossari Biotech Limited appoints Mr. Manikantan Viswanathan as Group CFO

Rossari Biotech Limited to commission greenfield facility at Dahej by March 2021

Muthoot Finance Ltd board to consider Q2FY21 results on Nov 3, 2020

Subex Ltd allots 56,20,02,935 equity shares pursuant to capital reduction

Edelweiss Financial Services Limited board to approve Q2 results on Oct 30, 2020

Vedanta Limited board approves first interim dividend of Rs. 9.50

Calcom Vision Ltd posts Q2FY21 PAT of Rs. 0.33 crore

Rossari Botech Ltd Q2FY21 consolidated net profit higher at Rs. 20.69 crore

Vardhman Textiles Ltd reports Rs. 60.22 crore consolidated PAT in Q2FY21

ICICI Bank gets approval for closing down operations in Sri Lanka

Aditya Vision Limited opens 51st showroom at Manpur, Gaya, Bihar

Ashoka Kandi Ramsanpalle Road Pvt Ltd receives financial closure letter from NHAI

Jasch Industries Ltd Q2FY21 PAT at Rs. 1.83 crore

The Anup Engineering Ltd board to announce Q2FY21 results on Oct 31, 2020

ZF Steering Gear India Ltd Q2FY21 loss at Rs. 0.97 crore

Polycab India Ltd Q2FY21 consolidated PAT rises to Rs. 220.54 crore

KSB Limited to invest in solar power plant SPV

Redington Gulf omcreases stake in Citrus to 100%

Ultramarine & Pigments Ltd board to announce Q2FY21 results on Nov 10, 2020

Mr. Raghav Bahl, promoter of Quint Digital Media Limited decides against converting bulk of the warrants

ITC Ltd board to consider Q2, H1 results on Nov 6, 2020

Persistent Systems Limited appoints Mr. Sandeep Kalra as CEO

Persistent Systems Ltd Q2FY21 consolidated net profit climbs to Rs. 101.98 crore

DXC Technology India Pvt Ltd announces Rs. 56.50 as indicative price for delisting offer of Xchanging Solutions Limited

Huhtamaki PPL Ltd Q3CY20 net profit at Rs. 36.88 crore

LIC Raises Stake to 5.27% in IRB Infrastructure Developers Ltd.

Nestle India Ltd appoints Mr. Matthias C Lohner as Executive Director - Technical

Bank of Baroda approves issue of Basel III compliant AT-1 bonds for Rs. 2755 crore

Punjab & Sind Bank declares IFIN NPA account as fraud

Asian Granito India Ltd Board approves sub-division of equity shares

Supreme Petrochem Ltd Board declares Interim Dividend of Rs. 2.50

Nestle India Ltd board declares interim dividend of Rs. 135

National Plastic Technologies Ltd Q2 PAT at Rs. 0.47 crore

Sudarshan Chemical Industries Ltd Q2FY21 consolidated net profit at Rs. 30.33 crore

Supreme Petrochem Ltd Q2FY21 PAT jumps to Rs. 86.15 crore

Nestle India Ltd posts Q3CY20 net profit of Rs. 587.09 crore

Zenith Steel Pipes & Industries Ltd issues equity shares at Rs. 10

Vippy Spinpro Ltd posts net profit of Rs. 0.75 crore in Q2FY21

Tech Mahindra Ltd arm to acquire Momenton

ICICI Lombard General Insurance Company Limited reports Q2FY21 earnings

Genus Power Infrastructures Ltd Q2FY21 consolidated net profit at Rs. 0.89 crore

Bhageria Industries Ltd Q2FY21 consolidated PAT at Rs. 16.15 crore

WABCO India Ltd posts Rs. 35.10 crore PAT in Q2FY21

Benares Hotels Ltd Q2 loss at Rs. 3.02 crore

Tech Mahindra Ltd Board declares special dividend of Rs. 15

Duncan Engineering Ltd reports net profit of Rs. 1.64 crore in Q2

Control Print Ltd Q2 consolidated PAT rises to Rs. 7.42 crore

Tech Mahindra Ltd arm to acquire Tenzing Group

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019